Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Mohamed A Kharfan-Dabaja; Myriam Labopin; Ali Bazarbachi; Gerard Socie; Nicolaus Kroeger; Didier Blaise; Hendrik Veelken; Arancha Bermudez; Reuven Or; Bruno Lioure; Dietrich Beelen; Nathalie Fegueux; Rose Marie Hamladji; Arnon Nagler; Mohamad Mohty

doi:10.1016/j.leukres.2015.04.009

Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Standard

Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. / Kharfan-Dabaja, Mohamed A; Labopin, Myriam; Bazarbachi, Ali; Socie, Gerard; Kroeger, Nicolaus; Blaise, Didier; Veelken, Hendrik; Bermudez, Arancha; Or, Reuven; Lioure, Bruno; Beelen, Dietrich; Fegueux, Nathalie; Hamladji, Rose Marie; Nagler, Arnon; Mohty, Mohamad.

in: LEUKEMIA RES, Jahrgang 39, Nr. 9, 09.2015, S. 933-7.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kharfan-Dabaja, MA, Labopin, M, Bazarbachi, A, Socie, G, Kroeger, N, Blaise, D, Veelken, H, Bermudez, A, Or, R, Lioure, B, Beelen, D, Fegueux, N, Hamladji, RM, Nagler, A & Mohty, M 2015, 'Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation', LEUKEMIA RES, Jg. 39, Nr. 9, S. 933-7. https://doi.org/10.1016/j.leukres.2015.04.009

APA

Kharfan-Dabaja, M. A., Labopin, M., Bazarbachi, A., Socie, G., Kroeger, N., Blaise, D., Veelken, H., Bermudez, A., Or, R., Lioure, B., Beelen, D., Fegueux, N., Hamladji, R. M., Nagler, A., & Mohty, M. (2015). Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. LEUKEMIA RES, 39(9), 933-7. https://doi.org/10.1016/j.leukres.2015.04.009

Vancouver

Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Socie G, Kroeger N, Blaise D et al. Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. LEUKEMIA RES. 2015 Sep;39(9):933-7. https://doi.org/10.1016/j.leukres.2015.04.009

Bibtex

@article{293f3c9c51ed46c58de88319b7a25e07,

title = "Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation",

abstract = "Allogeneic hematopoietic cell transplantation is a potentially curative treatment in patients with acute myeloid leukemia. Recent advances in the field of hematopoietic cell allografting have resulted in a practice shift, favoring less intense preparative regimens. We present results of a retrospective comparative analysis of two preparative regimens, namely FB2 (IV fludarabine plus IV busulfan 6.4mg/kg±10%) and FB4 (IV fludarabine plus IV busulfan 12.8mg/kg ±10%), in patients with acute myeloid leukemia undergoing hematopoietic cell allografting in second complete remission at EBMT participating centers. Between 2003 and 2010, 128 AML patients in second complete remission were allografted following a preparative regimen of FB2 (n=88) or FB4 (n=40). The median time-to-neutrophil engraftment was similar whether patients received FB2 (16 (5-38) days) or FB4 (16 (9-29) days), p=0.45. A multivariate analysis showed that use of FB4 resulted in improved 2-year leukemia-free (HR=0.44 (95%CI=0.21, 0.94), p=0.03) and overall survival (HR=0.38 (95%CI=0.16, 0.86), p=0.02). Cumulative incidence of non-relapse mortality (2-year) for all patients was 21% (95%CI=14-28%). Our analysis suggests that FB4 improves 2-year leukemia-free and overall survival in AML allografted in second complete remission. A confirmatory randomized controlled trial that compares these two preparative regimens (FB2 vs. FB4) in AML in CR2 is definitely warranted.",

keywords = "Adult, Aged, Antineoplastic Agents, Alkylating, Busulfan, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Multivariate Analysis, Randomized Controlled Trials as Topic, Remission Induction, Retrospective Studies, Survival Analysis, Transplantation Conditioning, Transplantation, Homologous, Vidarabine",

author = "Kharfan-Dabaja, {Mohamed A} and Myriam Labopin and Ali Bazarbachi and Gerard Socie and Nicolaus Kroeger and Didier Blaise and Hendrik Veelken and Arancha Bermudez and Reuven Or and Bruno Lioure and Dietrich Beelen and Nathalie Fegueux and Hamladji, {Rose Marie} and Arnon Nagler and Mohamad Mohty",

year = "2015",

month = sep,

doi = "10.1016/j.leukres.2015.04.009",

language = "English",

volume = "39",

pages = "933--7",

journal = "LEUKEMIA RES",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "9",

}

RIS

TY - JOUR

T1 - Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

AU - Kharfan-Dabaja, Mohamed A

AU - Labopin, Myriam

AU - Bazarbachi, Ali

AU - Socie, Gerard

AU - Kroeger, Nicolaus

AU - Blaise, Didier

AU - Veelken, Hendrik

AU - Bermudez, Arancha

AU - Or, Reuven

AU - Lioure, Bruno

AU - Beelen, Dietrich

AU - Fegueux, Nathalie

AU - Hamladji, Rose Marie

AU - Nagler, Arnon

AU - Mohty, Mohamad

PY - 2015/9

Y1 - 2015/9

N2 - Allogeneic hematopoietic cell transplantation is a potentially curative treatment in patients with acute myeloid leukemia. Recent advances in the field of hematopoietic cell allografting have resulted in a practice shift, favoring less intense preparative regimens. We present results of a retrospective comparative analysis of two preparative regimens, namely FB2 (IV fludarabine plus IV busulfan 6.4mg/kg±10%) and FB4 (IV fludarabine plus IV busulfan 12.8mg/kg ±10%), in patients with acute myeloid leukemia undergoing hematopoietic cell allografting in second complete remission at EBMT participating centers. Between 2003 and 2010, 128 AML patients in second complete remission were allografted following a preparative regimen of FB2 (n=88) or FB4 (n=40). The median time-to-neutrophil engraftment was similar whether patients received FB2 (16 (5-38) days) or FB4 (16 (9-29) days), p=0.45. A multivariate analysis showed that use of FB4 resulted in improved 2-year leukemia-free (HR=0.44 (95%CI=0.21, 0.94), p=0.03) and overall survival (HR=0.38 (95%CI=0.16, 0.86), p=0.02). Cumulative incidence of non-relapse mortality (2-year) for all patients was 21% (95%CI=14-28%). Our analysis suggests that FB4 improves 2-year leukemia-free and overall survival in AML allografted in second complete remission. A confirmatory randomized controlled trial that compares these two preparative regimens (FB2 vs. FB4) in AML in CR2 is definitely warranted.

AB - Allogeneic hematopoietic cell transplantation is a potentially curative treatment in patients with acute myeloid leukemia. Recent advances in the field of hematopoietic cell allografting have resulted in a practice shift, favoring less intense preparative regimens. We present results of a retrospective comparative analysis of two preparative regimens, namely FB2 (IV fludarabine plus IV busulfan 6.4mg/kg±10%) and FB4 (IV fludarabine plus IV busulfan 12.8mg/kg ±10%), in patients with acute myeloid leukemia undergoing hematopoietic cell allografting in second complete remission at EBMT participating centers. Between 2003 and 2010, 128 AML patients in second complete remission were allografted following a preparative regimen of FB2 (n=88) or FB4 (n=40). The median time-to-neutrophil engraftment was similar whether patients received FB2 (16 (5-38) days) or FB4 (16 (9-29) days), p=0.45. A multivariate analysis showed that use of FB4 resulted in improved 2-year leukemia-free (HR=0.44 (95%CI=0.21, 0.94), p=0.03) and overall survival (HR=0.38 (95%CI=0.16, 0.86), p=0.02). Cumulative incidence of non-relapse mortality (2-year) for all patients was 21% (95%CI=14-28%). Our analysis suggests that FB4 improves 2-year leukemia-free and overall survival in AML allografted in second complete remission. A confirmatory randomized controlled trial that compares these two preparative regimens (FB2 vs. FB4) in AML in CR2 is definitely warranted.

KW - Adult

KW - Aged

KW - Antineoplastic Agents, Alkylating

KW - Busulfan

KW - Female

KW - Graft vs Host Disease

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Leukemia, Myeloid, Acute

KW - Male

KW - Middle Aged

KW - Multivariate Analysis

KW - Randomized Controlled Trials as Topic

KW - Remission Induction

KW - Retrospective Studies

KW - Survival Analysis

KW - Transplantation Conditioning

KW - Transplantation, Homologous

KW - Vidarabine

U2 - 10.1016/j.leukres.2015.04.009

DO - 10.1016/j.leukres.2015.04.009

M3 - SCORING: Journal article

C2 - 26003666

VL - 39

SP - 933

EP - 937

JO - LEUKEMIA RES

JF - LEUKEMIA RES

SN - 0145-2126

IS - 9

ER -